Cell Design Labs

This page shows the latest Cell Design Labs news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Among Gilead's moves is a shift into immuno-oncology via the acquisition of CAR-T specialist Kite Pharma for almost $12bn and smaller player Cell Design Labs, a $3bn agreement

Latest news

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Celgene is in talks with Juno Therapeutics about a possible takeover deal, right after cutting a $7bn deal to buy Impact Labs, according to media reports. ... Gilead followed the Kite deal with a smaller buyout of CAR-T firm Cell Design Labs last month.
Gilead adds to CAR-T assets with Cell Design Labs buyout

Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is boosting its position in the category with a $567m swoop on Cell Design ... for a green light from the FDA for Kymriah (tisagenlecleucel) as a treatment

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells). ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....